Characterization of CD22 expression in acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 62, Issue 6, 2015, Pages 964-969

  Shah, Nirali N ^a   Stevenson, Maryalice Stetler ^a   Yuan, Constance M ^a   Richards, Kelly ^a   Delbrook, Cindy ^a   Kreitman, Robert J ^a   Pastan, Ira ^a   Wayne, Alan S ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acute lymphoblastic leukemia; CD22; Monoclonal antibody; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; CD22 ANTIGEN; CD22 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHROMOSOME 11Q; CHROMOSOME REARRANGEMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; PRE B LYMPHOCYTE; PRIORITY JOURNAL; YOUNG ADULT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CHROMOSOME 11; GENETICS; IMMUNOLOGY; INFANT; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 11; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; INFANT; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIALIC ACID BINDING IG-LIKE LECTIN 2;

EID: 84927788910     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25410     Document Type: Article

References (30)

1. Gloeckler Ries L, Mortality CC, In: Reis LAG, Smith SM, Gurney JG, et al (eds). Cancer Incidence and Survival among Children and Adolescents: SEER Program 1975-1995. NIH Pub. No. 99-4649 Bethesda. United States: National Cancer Institute 1999. pp 165-170.
2. Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 2010; 28:648-654.
3. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355:1572-1582.
4. Law CL, Aruffo A, Chandran KA, Doty RT, Clark EA. Ig domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind multiple sialylated ligands expressed on B and T cells. J Immunol 1995; 155:3368-3376.
5. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annual review of immunology 1997; 15:481-504.
6. Tedder TF, Poe JC, Haas KM. CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction. Advances in immunology 2005; 88:1-50.
7. Clark EA. CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J Immunol 1993; 150:4715-4718.
8. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A Children's Oncology Group Pilot Study. J Clin Oncol 2008; 26:3756-3762.
9. Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013; 119:2728-2736.
10. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012; 30:1822-1828.
11. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, Fitzgerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ. Anti -CD22-chimeric antigen receptors targeting B cell precursor acute lymphoblastic leukemia. Blood. 2013; 121:1165-1174.
12. Hoelzer D, Gokbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012; 26:25-32.
13. Raponi S, De Propris MS, Intoppa S, Milani ML, Vitale A, Elia L, Perbellini O, Pizzolo G, Foa R, Guarini A. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: Analysis of 552 cases. Leuk Lymphoma 2011; 52:1098-1107.
14. Piccaluga PP, Arpinati M, Candoni A, Laterza C, Paolini S, Gazzola A, Sabattini E, Visani G, Pileri SA. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma 2011; 52:325-327.
15. Chevallier P, Robillard N, Houille G, Ayari S, Guillaume T, Delaunay J, Harousseau JL, Avet-Loiseau H, Mohty M, Garand R. Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: A monocentric study of 44 cases. Leukemia 2009; 23:806-807.
16. Iwamoto S, Deguchi T, Ohta H, Kiyokawa N, Tsurusawa M, Yamada T, Takase K, Fujimoto J, Hanada R, Hori H, Horibe K, Komada Y. Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: Report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol 2011; 94:185-192.
17. Singh R, Zhang Y, Pastan I, Kreitman RJ. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. Clin Cancer Res 2012; 18:152-160.
18. Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, Hassan R, Pastan I. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer research 2010; 70:1082-1089.
19. Jasper GA, Arun I, Venzon D, Kreitman RJ, Wayne AS, Yuan CM, Marti GE, Stetler-Stevenson M. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom 2011; 80:83-90.
20. Schwartz A, Marti GE, Poon R, Gratama JW, Fernandez-Repollet E. Standardizing flow cytometry: A classification system of fluorescence standards used for flow cytometry. Cytometry 1998; 33:106-114.
21. Stetler-Stevenson M, Ahmad E, Barnett D, Braylan RC, DiGiuseppe JA, Marti G, Menozzi D, Oldaker TA, Orfao A, Rabellino E, Stone EC. C W Clinical and Laboratory Standards Institute. Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline- Second Edition. CLSI document. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute 2005. pp A2-H43.
22. Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ. Soluble CD22 as a tumor marker for hairy cell leukemia. Blood 2008; 112:2272-2277.
23. Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cell are sufficient for complete responses. Cancer research 1998; 58:968-975.
24. Ogata M, Chaudhary VK, Pastan I, FitzGerald DJ. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37, 000-Da toxin fragment that is translocated to the cytosol. The Journal of biological chemistry 1990; 265:20678-20685.
25. Jansen MW, Corral L, van der Velden VH, Panzer-Grumayer R, Schrappe M, Schrauder A, Marschalek R, Meyer C, den Boer ML, Hop WJ, Valsecchi MG, Basso G, Biondi A, Pieters R. Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia 2007; 21:633-641.
26. Kennedy GA, Tey SK, Cobcroft R, Marlton P, Cull G, Grimmett K, Thomson D, Gill D. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: A retrospective review. Br J Haematol 2002; 119:412-416.
27. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. The New England journal of medicine 2013; 368:1509-1518.
28. Zhang Y, Pastan I. High shed antigen levels within tumors: An additional barrier to immunoconjugate therapy. Clin Cancer Res 2008; 14:7981-7986.
29. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, Fitzgerald DJ, Pastan I. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: Preclinical studies and phase I clinical trial. Clin Cancer Res 2010; 16:1894-1903.
30. Wood BL, Arroz M, Barnett D, DiGiuseppe J, Greig B, Kussick SJ, Oldaker T, Shenkin M, Stone E, Wallace P. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom 2007; 72:S14-S22.